Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Panacos Pharmaceuticals (PANC) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (10)	10/26/2006 4:59:42 PM
From: dr.praveen	Respond to of 53

Recent Business Highlights: • The Company continued to advance its Phase 2b study of bevirimat (PA-457) in treatment-experienced patients failing current therapy in combination with approved HIV drugs. The goal of the study is to select the most appropriate dose(s) to take into pivotal Phase 3 trials. • The Company recently released the results of a preclinical study that indicates bevirimat is non-teratogenic, meaning it did not cause fetal malformations in the models used in this study. These results suggest that bevirimat may not be teratogenic when used to treat HIV-infected pregnant women. • The Company also presented an update on its HIV fusion inhibitor program at the XVI International AIDS Conference in Toronto, indicating that the Panacos compounds have very high potency and a unique molecular target within the viral surface proteins, distinct from the currently-marketed HIV fusion inhibitor FUZEON. • The Company announced the addition of Dr. Laurent Fischer, M.D., to the Company's Board of Directors. Dr. Fischer, currently the President and CEO of Ocera Therapeutics, Inc., has extensive experience in developing and commercializing HIV drugs both at Dupont Pharmaceuticals and at Hoffmann LaRoche. "In the third quarter, Panacos made continued progress in our bevirimat development program and our pipeline programs," commented Peyton J. Marshall, CFO and Acting CEO of Panacos. "The Phase 2b trial is clearly a major step in bevirimat's development, and we expect initial data for the first cohort before year-end and data from subsequent cohorts in the following quarters."

To: tuck who wrote (10)	11/1/2006 7:21:45 PM
From: dr.praveen	Respond to of 53

Panacos Appoints Scott McCallister, M.D., Chief Medical Officer Wednesday November 1, 4:02 pm ET <Getting closer to the results:-) Any guess if they are in Nov r Dec? > WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC - News), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that Scott McCallister, M.D. has joined the Company as Chief Medical Officer. Dr. McCallister will be responsible for medical affairs and will spearhead the Company's Phase 3 development efforts for bevirimat. He will report to Graham Allaway, Ph.D., Panacos' President and COO. Before joining Panacos, Dr. McCallister was Director of Virology, Global Medical Affairs for Bristol Myers Squibb Company (BMS). In this role, he was responsible for the global medical strategy of the anti-HIV protease inhibitor, atazanavir (REYATAZ), and coordinated the review and approval of other virology studies, both internal and external, at BMS. Prior to BMS, Dr. McCallister held positions of increasing responsibility at Boehringer Ingelheim Pharmaceuticals (BI), leading the international clinical development program and regulatory review process for its anti-HIV protease inhibitor, tipranivir (APTIVUS). At BI, Dr. McCallister coordinated the design, conduct, and analysis of more than 20 Phase I, II, and III tipranavir development trials, culminating in the FDA and EMEA approval of APTIVUS for the treatment of HIV infection in treatment-experienced patients. Dr. McCallister has also served as an Assistant Professor of Medicine at Rush Medical College, Medical Director of the Howard Brown Health Center, and Associate Chief of HIV Medicine at the Illinois Masonic Medical Center in Chicago, where he established a general HIV clinic, a drop-in sexually transmitted disease clinic, and a women's health clinic for indigent patients. Dr. McCallister completed his studies at St. George's University School of Medicine and the University of California, Los Angeles. Graham Allaway commented, "We are pleased to welcome Scott to the Panacos team. The expertise and experience he has gained in bringing an HIV drug from Phase 2 through regulatory approval will be extremely valuable to Panacos. His background will be a great addition to the bevirimat development program and to our HIV pipeline programs. Scott will work closely with Dr. David Martin, our Senior Vice President of Drug Development, as bevirimat moves toward Phase 3 development."